The broader enforcement focus: Botox-type products, ophthalmics, clinical trials, recalls The RAPS article also highlights other key enforcement priorities for CDER in 2025: The agency issued 18 warning letters to firms marketing fraudulent or unapproved Botox-type products, warning that such products pose serious safety risks, including potential counterfeiting, incorrect/inactive ingredients, or falsification
Gallbladder disease -- rapid weight loss raises gallstone risk
Medical risks: pancreatitis history, kidney disease, pregnancy plans, or eating disorder history
There's something powerful about giving your liver exactly what it needs, when it needs it, without the hassle of driving across Phoenix traffic or sitting in waiting rooms
Philippines FDA Registration Number: DR-XY39340